1月7日，港股三大指数全天疲弱，市场连续反弹后做多情绪表现谨慎。恒生科技指数午后一度大跌至2.4%，最终收跌1.49%，恒生指数、国企指数分别下跌 0.94%及1.14%。 | 名称 | | 最新价 | 涨跌额 | 涨跌幅 | | --- | --- | --- | --- | --- | | 恒生指数 | | 26458.95 | -251.50 | -0.94% | | 800000 | | | | | | 国企指数 | | 9138.75 | -105.49 | -1.14% | | 800100 | No | | | | | 恒生科技指数 | | 5738.52 | -86.74 | -1.49% | | 800700 | NV | | | 国商都 | 盘面上，大型科技股集体下跌拖累市场走低，阿里巴巴跌超3%，网易、快手跌超2%；昨日领衔大市上涨的中资券商股、保险股承压明显；汽车板块跌幅居 前，比亚迪股份、蔚来汽车、小鹏汽车跌幅明显；石油股、脑机接口、内房股、苹果概念股纷纷下跌。另一方面，纸业板块领涨，玖龙纸业一度大涨12%刷 新阶段新高；创新药、光伏、煤炭、餐饮股齐涨。 | 行业热力图 × | 领涨 ...

新华财经上海12月12日 数据显示，2025年，中国创新药"出海"金额逾千亿美元，在研新药数量跃居全 球第二。 然则，登高望远，方觉任重道远——创新药"仿创"底色犹浓，且面临靶点集中、源头创新乏力等深层次 挑战。"难关"在前，破局思路日渐清晰：开放医保数据应用，从需求侧为产业导航；强化产学研协同， 构建创新生态圈；探索差异化出海路径，深化与跨国药企合作…… 多措并举之下，中国创新药产业正从"跟跑"向"引领"加速转型。 制度"破冰"：医保数据开闸与支付改革破局 近日，赛麦德咨询在上海浦东正式发布"2025中国医药创新指数"。从新药研发、技术转化、商业化落地 等多个层面，系统评估了中国本土制药企业的综合创新能力。 对此，业内人士表示，该指数的发布，也让中国创新药产业更加"可评估、可对标、可引导"。 "2025年我国创新药出海金额已经突破1000亿美元。从三生制药与辉瑞的创记录合作，到信达生物与武 田的共同开发、共同商业化的合作模式，这些突破性的授权不仅是商业上的成功，更标志着中国创新已 经跃升为兼具价值兑现、能力建设、全球布局的复合型模式。"赛麦德咨询亚太区总裁邓显鹏表示。 当前，政策支撑体系也在加速完善。202 ...

Group 1 - The core viewpoint of the article highlights that the clarification of national medical insurance policies is expected to boost the innovative drug industry, marking the beginning of a policy dividend period for innovative drugs [1] - The National Medical Insurance Administration has established the principle of "new drugs not subject to centralized procurement, and centralized procurement applies to non-new drugs," which alleviates market concerns regarding the inclusion of innovative drugs in centralized procurement [1] - This policy clarity allows companies to more accurately formulate research and development plans and increase investment in core therapeutic areas, enhancing the predictability of returns on innovative drug R&D [1] Group 2 - The medical device industry is entering a dual-driven period of policy and technology, with domestic substitution and technology going abroad becoming core trends [1] - The dynamic adjustment mechanism of the medical insurance catalog and centralized procurement policies work in synergy, making the commercialization path for innovative drugs smoother and shortening the cycle from R&D to commercialization [1] - The favorable policies are expected to accelerate the R&D projects of domestic innovative drug companies in areas such as oncology and autoimmune diseases, thereby enhancing the global competitiveness of China's pharmaceutical industry [1] Group 3 - The medical ETF (159828) has risen over 2.0%, reflecting the positive impact of these policy changes on the market [1] - The medical ETF tracks the CSI Medical Index (399989), which selects listed companies involved in medical devices, medical services, and medical information technology from the Shanghai and Shenzhen A-share markets [1] - Investors without stock accounts can consider the GTJA CSI Medical ETF Connect A (012634) and GTJA CSI Medical ETF Connect C (012635) [1]